<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442272</url>
  </required_header>
  <id_info>
    <org_study_id>NEFROVID2010</org_study_id>
    <nct_id>NCT01442272</nct_id>
  </id_info>
  <brief_title>Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D</brief_title>
  <acronym>NEFROVID2010</acronym>
  <official_title>Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the value the additional antiproteinuric effects of
      vitamin D derivatives treatment, in patients with Chronic Kidney Illness phase II-IV, with
      lack of vitamin D and residual proteinuria higher 0,5 grams/day.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protein/creatinine quotient and albumin/creatinine in matinal urine sample: basal and 3 period months after a month of the therapeutic protocol beginning.</measure>
    <time_frame>1-3 month</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Disorder of Vitamin D</condition>
  <arm_group>
    <arm_group_label>Habitual medication withuot additional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual medication plus Hidroferol®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual medication plus Zemplar®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hidroferol®</intervention_name>
    <description>Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months</description>
    <arm_group_label>Habitual medication plus Hidroferol®</arm_group_label>
    <other_name>B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol: Zemplar®</intervention_name>
    <description>Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months</description>
    <arm_group_label>Habitual medication plus Zemplar®</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Habitual medication</intervention_name>
    <description>Habitual medication</description>
    <arm_group_label>Habitual medication withuot additional</arm_group_label>
    <other_name>A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female Patients older 18 years old

          -  Patients have signed written informed consent

          -  Chronic Kidney Illness phase II-IV plus residual proteinuria &gt;0,5 grams/day (two or
             more consecutive occasions) and plus beta blockers treatment from AARS during al least
             3 months.

          -  Serum levels of calcifediol in the lack of level (15-30 ng/ml).

        Exclusion Criteria:

          -  Bad control of high blood pressure (higher or same 180/110 mmHg)

          -  Bad control of diabetes (HbA1c higher 9,5 in the last three months period)

          -  Hypercalcemia (&lt;10,2 mg/dL) o hyperphosphatemia(&gt;5,5 mg/dL), CaxPO4&gt;50, hypercalciuria
             (urin Ca/Cr quotient &gt; 0,15)

          -  Vitamin D treatment or any analogous

          -  Hepatic failure ( AST o ALT &gt; 3 times higher than normal limit)

          -  medical history of poor nutrient intestinal absorptions or chronic diarrhea

          -  Active nephrolithiasis

          -  Treatment with medication wich can change vitamin D metabolism (phenobarbital,
             phenytoin, rifampicin)

          -  Participation in other Clinic Trial in 3 last months

          -  Active Alcoholism

          -  Neoplasia precedent (except cutaneous no melanoma)

          -  Pregnant women or while breastfeeding

          -  Vitamin D hypersensitivity or any its excipient hypersensitivity

          -  Any other condition from Research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Aldea</last_name>
    <phone>+34922678115</phone>
    <email>a.aldea@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>S/C Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Aldea</last_name>
      <phone>+34922678115</phone>
      <email>a.aldea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Victor Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUC</name>
      <address>
        <city>La Laguna</city>
        <state>S/c Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANA ALDEA</last_name>
      <phone>+34922678115</phone>
      <email>a.aldea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Victor Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

